BioStem Technologies (OTCMKTS:BSEM - Get Free Report) announced its quarterly earnings data on Monday. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.31, Zacks reports. The firm had revenue of $10.29 million for the quarter, compared to analyst estimates of $86.69 million.
BioStem Technologies Stock Down 3.8 %
BSEM stock traded down $0.48 during trading on Friday, hitting $12.25. 96,304 shares of the company's stock traded hands, compared to its average volume of 66,340. The stock has a market capitalization of $204.61 million, a price-to-earnings ratio of 18.01 and a beta of 0.09. BioStem Technologies has a 52 week low of $6.77 and a 52 week high of $28.26. The stock has a fifty day moving average price of $11.31 and a two-hundred day moving average price of $13.74.
BioStem Technologies Company Profile
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Featured Stories
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
